Zhang Xing-Mao, Fan Hua, Kou Jian-Tao, Zhang Xin-Xue, Li Ping, Dai Yang, He Qiang
Department of Hepatobiliary Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
J Gastroenterol Hepatol. 2016 Aug;31(8):1498-503. doi: 10.1111/jgh.13299.
There is still controversy on the outcomes of portal vein (PV) and/or superior mesenteric vein (SMV) resection in pancreatic cancer, and there are few reports about pancreaticoduodenectomy (PD) with PV/SMV resection and reconstruction by using allogeneic vein. This study is to explore the outcomes of PD with PV/SMV resection and reconstruction by using allogeneic vein for pT3 pancreatic cancer with venous invasion.
Clinicopathological data of patients underwent PD with en bloc resection of PV/SMV and reconstruction by using internal iliac from August 20, 2013 to July 25, 2015 were collected and the data of patients with pT3 stage pancreatic head cancer with PV/SMV invasion were analyzed. The short- and long-term outcomes were presented.
Thirty patients met the criteria of this study. PV resection and reconstruction were performed for 12 patients, SMV for 9 patients, and PV + SMV for 9 patients, respectively. The median operation time was 460 min, and the median intraoperative blood loss was 450 mL. R0 resection rate was 93.3%, total incidence of complications was 23.3%, and incidence of pancreatic fistula was 10%. The 1-year and 2-year overall survival rates were 68.6% and 39.2%, 1-year and 2-year disease free survival rates were 44.8% and 17.1%.
PD with en bloc resection of PV/SMV and reconstruction by using allogeneic vein was safe and feasible for patients with pT3 stage pancreatic head cancer with PV/SMV invasion. A large-scale research with longer follow-up time is required to draw a significant conclusion.
胰腺癌门静脉(PV)和/或肠系膜上静脉(SMV)切除的疗效仍存在争议,关于采用同种异体静脉进行PV/SMV切除及重建的胰十二指肠切除术(PD)的报道较少。本研究旨在探讨采用同种异体静脉对伴有静脉侵犯的pT3期胰腺癌行PV/SMV切除及重建的PD的疗效。
收集2013年8月20日至2015年7月25日期间接受PV/SMV整块切除并采用髂内静脉重建的PD患者的临床病理资料,并分析伴有PV/SMV侵犯的pT3期胰头癌患者的数据。呈现短期和长期疗效。
30例患者符合本研究标准。分别对12例患者进行了PV切除及重建,9例患者进行了SMV切除,9例患者进行了PV+SMV切除。中位手术时间为460分钟,中位术中出血量为450毫升。R0切除率为93.3%,并发症总发生率为23.3%,胰瘘发生率为10%。1年和2年总生存率分别为68.6%和39.2%,1年和2年无病生存率分别为44.8%和17.1%。
对于伴有PV/SMV侵犯的pT3期胰头癌患者,采用同种异体静脉进行PV/SMV整块切除及重建的PD是安全可行的。需要进行大规模、随访时间更长的研究才能得出有意义的结论。